XmAb TL1A x IL-23 Program (Xencor)

N/A

Report date: 2024/11/05 09:55:46

Base Information

Drug NameXmAb TL1A x IL-23 Program (Xencor)
Drug Alias NameXmAb TL1A x IL-23 bispecific antibody (Xencor)TL1A x IL-23 bispecific antibody (Xencor)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor superfamily member 15Interleukin-23 subunit p19 inhibitors
TargetsTumor necrosis factor superfamily member 15Interleukin-23 subunit p19
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A